Fig. 6: Survival curves of patients with high FLT3/ITD AR AML patients according to different treatment strategy.

A Probability of EFS for patients with and without GO treatment. B Probability of OS for patients with and without GO treatment. C Probability of EFS for patients with high FLT3/ITD AR according different treatment strategy. D Probability of OS for patients with high FLT3/ITD AR according to different treatment strategy. AML acute myeloid leukemia, SCT stem cell transplantation, GO Gemtuzumab Ozogamicin, AR allelic ratio, EFS event-free survival, OS overall survival. EFS and OS were evaluated by the Kaplan–Meier method and compared by log-rank test. Source data are provided as a Source Data file.